GlassScriptPhysician profile
Rani S Reddy
NPI 1841218013
$3,698.59
in general payments reported to CMS, 2019-2025
32 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $246 · 2021: $201 · 2022: $606 · 2023: $1,094 · 2024: $696 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,188.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $446.85 | 2019-2024 | Farxiga, Airsupra |
| Abbvie INC. | $426.48 | 2022-2025 | |
| Novo Nordisk INC | $335.86 | 2019-2025 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $269.77 | 2022-2024 | Austedo, Austedo Xr |
| Lilly USA, LLC | $230.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $215.98 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $194.19 | 2023-2025 | |
| Amgen INC. | $184.36 | 2021-2025 | Otezla, Repatha, Evenity |
| Axsome Therapeutics, INC. | $170.67 | 2023 | Auvelity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $165.07 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $149.52 | 2019-2024 | Fanapt |
| Abbott Laboratories | $149.39 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $102.04 | 2019-2025 | |
| Boston Scientific Corporation | $69.04 | 2019-2025 | Watchman Access System |
| Exact Sciences Corporation | $64.61 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $63.69 | 2023 | Gvoke Hypopen |
| Medtronic, INC. | $56.38 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $45.40 | 2023 | Trudhesa |
| Janssen Pharmaceuticals, INC | $36.38 | 2020-2021 | |
| Allergan, INC. | $35.85 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $35.29 | 2024 | Voquezna |
| Harmony Biosciences LLC | $35.24 | 2025 | |
| Sanofi-Aventis U.S. LLC | $26.02 | 2019-2022 | |
| Dexcom, INC. | $24.84 | 2024 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $24.80 | 2023 | Crysvita |
| Beta Bionics, INC. | $24.39 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Philips North America LLC | $23.87 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Mylan Specialty L.P. | $23.03 | 2024 | Yupelri |
| Esperion Therapeutics, INC. | $21.18 | 2021 | |
| Glaxosmithkline, LLC. | $19.84 | 2024 | Arexvy, Shingrix |
| Lundbeck LLC | $15.00 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $13.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rani Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.